IL218621B - An isolated antibody that binds the gammac domain of fibrin or fibrinogen - Google Patents
An isolated antibody that binds the gammac domain of fibrin or fibrinogenInfo
- Publication number
- IL218621B IL218621B IL218621A IL21862112A IL218621B IL 218621 B IL218621 B IL 218621B IL 218621 A IL218621 A IL 218621A IL 21862112 A IL21862112 A IL 21862112A IL 218621 B IL218621 B IL 218621B
- Authority
- IL
- Israel
- Prior art keywords
- gammmac
- fibrinogen
- fibrin
- binds
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 | |
| PCT/US2010/050873 WO2011041518A1 (en) | 2009-10-02 | 2010-09-30 | Monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL218621A0 IL218621A0 (en) | 2012-05-31 |
| IL218621B true IL218621B (en) | 2018-07-31 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218621A IL218621B (en) | 2009-10-02 | 2012-03-14 | An isolated antibody that binds the gammac domain of fibrin or fibrinogen |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
| WO2013185055A1 (en) | 2012-06-07 | 2013-12-12 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of pin1 |
| EP2968548B1 (en) * | 2013-03-15 | 2020-09-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| EP3091996B1 (en) * | 2014-01-11 | 2024-04-10 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions and methods for in vitro assays of fibrin activity |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| CA3178880A1 (en) | 2020-03-31 | 2021-10-07 | National Cancer Center | Fibrin-binding antibody and pharmaceutical composition containing antibody |
| WO2022133028A1 (en) * | 2020-12-16 | 2022-06-23 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Use of fibrin-targeting immunotherapy to reduce coronavirus pathogenesis |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| US20240279321A1 (en) * | 2021-06-18 | 2024-08-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE |
| WO2022266539A2 (en) * | 2021-06-18 | 2022-12-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| WO2024044583A1 (en) * | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
| EP4676499A2 (en) * | 2023-03-10 | 2026-01-14 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods and compositions for cellular immunotherapy- fib4 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| EP2314620B1 (en) * | 2004-05-27 | 2013-06-05 | Crucell Holland B.V. | Method of identifying binding molecules capable of neutralizing rabies virus |
| WO2007038407A2 (en) * | 2005-09-23 | 2007-04-05 | The Regents Of The University Of California | Compositions and methods for treating nervous system disorders |
-
2010
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 SM SM20170083T patent/SMT201700083T1/it unknown
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko not_active Expired - Fee Related
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en not_active Ceased
- 2010-09-30 PH PH1/2012/500551A patent/PH12012500551A1/en unknown
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
-
2017
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL218621B (en) | An isolated antibody that binds the gammac domain of fibrin or fibrinogen | |
| ZA201102119B (en) | Improved antibody libraies | |
| ZA201104545B (en) | Anti-siglec-15 antibody | |
| SG10201601279SA (en) | Monoclonal Antibody STRO-4 | |
| PT2374883T (pt) | Anticorpo anti-cd4 | |
| PT2146745E (pt) | Anticorpo pentaespecífico | |
| AU2013207589A1 (en) | Anti-Siglec-15 Antibody | |
| EP2138576A4 (en) | ANTI-CLAUDIN-4 ANTIBODY | |
| IL215771A0 (en) | Tri-or tetraspecific antibodies | |
| EP1987064A4 (en) | DOMAIN ANTIBODY CONSTRUCT | |
| EP2331579A4 (en) | MONOCLONAL ANTIBODIES | |
| ZA201006546B (en) | Hot-melt adhesives having lengthened open time | |
| DE602007005109D1 (de) | Verschlussanordnung für behälter | |
| IL205073A0 (en) | Anti-bst2 antibody | |
| PL2183985T3 (pl) | Określanie ścieżki pochodzenia | |
| EP2318436A4 (en) | ANTIBODIES OF DIFFERENT DOMAINS | |
| BRPI1013520A2 (pt) | ferro de passar | |
| GB2473934B (en) | Anti-VEEV antibody | |
| GB0911770D0 (en) | Antibody | |
| EP2264071A4 (en) | ANTIBODY WITH AN IMMUNE-REINFORCING FUNCTION | |
| AU2009902142A0 (en) | Variant domain antibodies | |
| PT2567237E (pt) | Ensaio de rastreio para a confirmação da vdcj | |
| GB0911712D0 (en) | Antibody | |
| GB0817622D0 (en) | Antibody | |
| GB0817621D0 (en) | Antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |